FPRX insider filings
FIVE PRIME THERAPEUTICS, INC. — 34 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-04-19. Screen FPRX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for FPRX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — FIVE PRIME THERAPEUTICS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2021-04-19 | 4 | Collins Helen Louise — EVP and Chief Medical Officer | Gift (G): 8,085 @ $0 · Grant/award (A): 66,000 @ $0 · Disposition to issuer (D): 135,547 @ $38 · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 58,000 (derivative) · +3 more | EDGAR |
| 2021-04-19 | 4 | Nicholson Garry A — Director | Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2021-04-19 | 4 | Sarena Francis Willard — Chief Strategy Officer | Gift (G): 2,385 @ $0 · Gift (G): 795 @ $0 · Gift (G): 795 @ $0 · Gift (G): 795 @ $0 · Gift (G): 1,440 @ $0 · Gift (G): 2,460 @ $0 · +16 more | EDGAR |
| 2021-04-19 | 4 | Smith David V — Executive Vice President & CFO | Grant/award (A): 66,000 @ $0 · Disposition to issuer (D): 138,947 @ $38 · Disposition to issuer (D): 185,000 (derivative) · Disposition to issuer (D): 90,000 (derivative) · Disposition to issuer (D): 90,000 (derivative) | EDGAR |
| 2021-04-19 | 4 | White David — See Remarks | Disposition to issuer (D): 33,423 @ $38 · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2021-04-19 | 4 | RINGO WILLIAM R — Director | Gift (G): 10,000 @ $0 · Disposition to issuer (D): 16,600 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · +8 more | EDGAR |
| 2021-04-19 | 4 | BERGER FRANKLIN M — Director | Disposition to issuer (D): 5,000 @ $38 · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2021-04-19 | 4 | Dhingra Kapil — Director | Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2021-04-19 | 4 | Jensen Peder — Director | Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2021-04-19 | 4 | SCHAFER CAROL — Director | Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 1,250 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2021-04-19 | 4 | Lyons-Williams Lori — Director | Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2021-04-19 | 4 | Civik Thomas — President and CEO, Director | Disposition to issuer (D): 68,971 @ $38 · Disposition to issuer (D): 480,000 (derivative) | EDGAR |
| 2021-04-13 | 4 | Civik Thomas — President and CEO, Director | Tax withholding (F): 11,088 @ $37.94 | EDGAR |
| 2021-03-02 | 4 | Sarena Francis Willard — Chief Strategy Officer | Tax withholding (F): 1,158 @ $22.23 | EDGAR |
| 2021-03-02 | 4 | Collins Helen Louise — EVP and Chief Medical Officer | Tax withholding (F): 1,158 @ $22.23 | EDGAR |
| 2021-03-02 | 4 | White David — See Remarks | Tax withholding (F): 1,461 @ $22.23 | EDGAR |
| 2021-02-26 | 4 | Sarena Francis Willard — Chief Strategy Officer | Tax withholding (F): 5,100 @ $25.71 · Tax withholding (F): 1,653 @ $23.08 | EDGAR |
| 2021-02-26 | 4 | Collins Helen Louise — EVP and Chief Medical Officer | Tax withholding (F): 5,091 @ $25.71 · Tax withholding (F): 1,653 @ $23.08 | EDGAR |
| 2021-02-26 | 4 | Smith David V — Executive Vice President & CFO | Tax withholding (F): 5,110 @ $25.71 | EDGAR |
| 2021-02-26 | 4 | White David — See Remarks | Tax withholding (F): 1,155 @ $25.71 | EDGAR |
| 2020-12-15 | 4 | Sarena Francis Willard — Chief Strategy Officer | Option exercise (M): 22,000 @ $0 · Tax withholding (F): 11,583 @ $16.14 · Option exercise (M): 22,000 (derivative) @ $0 | EDGAR |
| 2020-12-15 | 4 | Smith David V — Executive Vice President & CFO | Option exercise (M): 22,000 @ $0 · Tax withholding (F): 11,504 @ $16.14 · Option exercise (M): 22,000 (derivative) @ $0 | EDGAR |
| 2020-12-15 | 4 | Collins Helen Louise — EVP and Chief Medical Officer | Option exercise (M): 22,000 @ $0 · Tax withholding (F): 11,583 @ $16.14 · Option exercise (M): 22,000 (derivative) @ $0 | EDGAR |
| 2020-11-30 | 4 | Smith David V — Executive Vice President & CFO | Tax withholding (F): 6,920 @ $18.45 | EDGAR |
| 2020-11-13 | 4 | Sarena Francis Willard — Chief Strategy Officer | Option exercise (M): 22,000 @ $0 · Tax withholding (F): 11,001 @ $18 · Option exercise (M): 22,000 (derivative) @ $0 | EDGAR |
| 2020-11-13 | 4 | Smith David V — Executive Vice President & CFO | Option exercise (M): 22,000 @ $0 · Tax withholding (F): 10,908 @ $18 · Option exercise (M): 22,000 (derivative) @ $0 | EDGAR |
| 2020-11-13 | 4 | Collins Helen Louise — EVP and Chief Medical Officer | Option exercise (M): 22,000 @ $0 · Tax withholding (F): 11,039 @ $18 · Option exercise (M): 22,000 (derivative) @ $0 | EDGAR |
| 2020-11-13 | 4 | RINGO WILLIAM R — Director | Option exercise (M): 52,959 @ $2.22 · Sale (S): 52,959 @ $22.50 · Option exercise (M): 26,000 @ $2.80 · Sale (S): 26,000 @ $22.50 · Option exercise (M): 52,959 (derivative) @ $0 · Option exercise (M): 26,000 (derivative) @ $0 | EDGAR |
| 2020-11-13 | 4 | BVF PARTNERS L P/IL BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC/IL LAMPERT MARK N | Sale (S): 3,941,214 @ $20.19 · Sale (S): 2,949,477 @ $20.19 · Sale (S): 502,649 @ $20.19 | EDGAR |
| 2020-11-06 | 4 | BVF PARTNERS L P/IL — 10% owner BIOTECHNOLOGY VALUE FUND L P — 10% owner BVF I GP LLC — 10% owner BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC — 10% owner BVF INC/IL — 10% owner LAMPERT MARK N — 10% owner | Purchase (P): 257,804 @ $4.88 · Purchase (P): 17,230 @ $4.98 · Purchase (P): 143,403 @ $4.88 · Purchase (P): 10,436 @ $4.98 · Purchase (P): 15,355 @ $4.88 · Purchase (P): 2,334 @ $4.98 | EDGAR |
| 2020-10-08 | 4 | BVF PARTNERS L P/IL — 10% owner BIOTECHNOLOGY VALUE FUND L P — 10% owner BVF I GP LLC — 10% owner BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC — 10% owner BVF INC/IL — 10% owner LAMPERT MARK N — 10% owner | Purchase (P): 157,782 @ $5.04 · Purchase (P): 162,352 @ $5.04 · Purchase (P): 25,107 @ $5.04 | EDGAR |
| 2020-10-02 | 4 | White David — See Remarks | Tax withholding (F): 6,916 @ $4.70 | EDGAR |
| 2020-09-24 | 4 | BVF PARTNERS L P/IL — 10% owner BIOTECHNOLOGY VALUE FUND L P — 10% owner BVF I GP LLC — 10% owner BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC — 10% owner BVF INC/IL — 10% owner LAMPERT MARK N — 10% owner | Purchase (P): 32 @ $3.80 | EDGAR |
| 2020-08-24 | 4 | Collins Helen Louise — EVP and Chief Medical Officer | Tax withholding (F): 827 @ $4.69 | EDGAR |
Recent 8-K events — FIVE PRIME THERAPEUTICS, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2021-04-16 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-04-15 | 8-K | 8.01 — Other Events | EDGAR |
| 2021-03-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-01-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-01-15 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2020-11-17 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-11-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-11-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-11-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FPRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs